Abstract
The intratumoral delivery of radioactive therapeutics, a clinical technique known as brachytherapy, has proven very successful in treating solid cancers and become a prevalent option for treating prostate, breast, and melanoma tumors. The method typically involves the permanent implantation of 80-120 titanium ‘seeds’ encapsulating radioactive isotopes and requires expert spatial placement to ensure full dose coverage. The disadvantages of the seeds include a complicated implantation process, the permanence of the implants, migration of seeds to off-target sites, and that the titanium shielding limits the application of radionuclides which could treat more aggressive forms of cancer. As such, we have developed a next-generation brachytherapy alternative to solid seeds using an injectable, biodegradable, biocompatible and thermosensitive elastin-like polypeptide (ELP). Through recombinant design and synthesis, ELP exhibits a thermal phase transition (soluble-to-insoluble) when heated above 21°C. This allows radionuclide-bearing ELP to be easily handled as a fluid at room temperature, but enables spontaneous self-assembly into a stable brachytherapy gel upon intratumoral injection at body temperature. Previously, we demonstrated the efficacy of ELP brachytherapy in treating both s.c. human hypopharyngeal tumors and orthotopic human prostate tumors xenografted in mice models.